Alexandra Teleki awarded SEK 4 million by The Erling-Persson Foundation
The Faculty of Pharmacy congratulates Alexandra Teleki, researcher with a focus on Pharmaceutical Nanotechnology, on receiving SEK 4 million from The Erling-Persson Foundation to develop new methods for the diagnosis and treatment of inflammatory bowel disease.
Alexandra Teleki, Associate Professor at the Department of Pharmacy, receives SEK 4 million kronor from The Erling-Persson Foundation, to continue the development of new methods to diagnose and treat inflammatory bowel disease. The work will be conducted in close collaboration with Mia Phillipson and Peter Thelin Schmidt at Uppsala University's Faculty of Medicine.
Mia Phillipson and Peter Thelin Schmidt, Uppsala University
“Our goal is to enable the diagnosis and treatment of inflammatory bowel disease in children without anesthesia or physical intervention, and to receive such generous support from The Erling-Persson Foundation, which truly shares our commitment to children's health, makes this grant very special for us,” says Alexandra Teleki.
The project Non-Invasive Diagnosis and Treatment Monitoring of Inflammatory Bowel Disease is a direct continuation of the work that TelekiLab started in 2021 with financial support from the ERC. In the next stage, the Magnetic Resonance Imaging (MRI) methods that the team has created will be the subject of further studies at Uppsala University's research environment for Positron Emission Tomography (PET).
“The grant from The Erling-Persson Foundation extends over three years, and with the important aid and combined expertise of Mia Phillipson, Professor of Physiology, and Peter Thelin Schmidt, Professor of Gastroenterology/Hepatology, we are all set to take the final steps towards clinical studies,” states Alexandra Teleki.
Facts
- Chronic inflammatory bowel diseases have long been a challenge in Europe and North America and are now spreading across Asia.
- Every fourth patient develops the disease as a child, and currently, sampling of biopsies under anesthesia is required to identify where in the gastrointestinal tract the inflammation is located and how active it is. Thereafter, healthcare can at best adapt the treatment to reduce the inflammation
- With funding from The Erling-Persson Foundation and the ERC, Alexandra Teleki leads the development of a method to use nanoparticles in order to both localize the inflammation and administer the drugs required to cure it.
Contact
Alexandra Teleki, Associate Professor
Department of Pharmacy
alexandra.teleki@farmaci.uu.se
text: Magnus Alsne, photo: Mikael Wallerstedt